

This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.

This English version is intended to be a reference material to provide convenience for users.

In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Revision of PRECAUTIONS

Ibrutinib

February 10, 2026

Therapeutic category

Other antitumor agents

Non-proprietary name

Ibrutinib

Safety measure

PRECAUTIONS should be revised.

*This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.
This English version is intended to be a reference material to provide convenience for users.
In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.*

Revised language is underlined.

Current	Revision
<p>8. IMPORTANT PRECAUTIONS (newly added)</p> <p>11. ADVERSE REACTIONS 11.1 Clinically Significant Adverse Reactions (Newly added)</p>	<p>8. IMPORTANT PRECAUTIONS <u>Uveitis may occur. Whether ocular abnormalities occur should be examined periodically. In addition, patients should be instructed to immediately seek medical attention if any ocular abnormalities are observed.</u></p> <p>11. ADVERSE REACTIONS 11.1 Clinically Significant Adverse Reactions <u>Uveitis</u></p>